FDA approves label expansion for ALUNBRIG® (brigatinib)
On June 26th, 2020
Takeda Oncology has announced that the US Food and Drug Administration (FDA) has approved the label expansion for ALUNBRIG® (brigatinib) to include patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are tyrosine kinase inhibitor (TKI)-naive. ALUNBRIG is indicated for the treatment of adult patients with ALK+ metastatic NSCLC as detected by an FDA-approved test. Please click here to review more information on ALUNBRIG and the safety information warnings.
Please click the link for ALUNBRIG full Prescribing Information.
To learn more about ALUNBRIG, please visit www.ALUNBRIG.com.
| Takeda Oncology has announced that the US Food and Drug Administration (FDA) has approved the label expansion for ALUNBRIG® (brigatinib) to include patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are tyrosine kinase inhibitor (TKI)-naive. ALUNBRIG is indicated for the treatment of adult patients with ALK+ metastatic NSCLC as detected by an FDA-approved test. Please click here to review more information on ALUNBRIG and the safety information warnings. |
Please click the link for ALUNBRIG full Prescribing Information. To learn more about ALUNBRIG, please visit www.ALUNBRIG.com. |
No comments have been posted yet.